Results 51 to 60 of about 38,358 (217)

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993

open access: yes, 2005
The international acute lymphoblastic leukemia (ALL) study was designed to prospectively define the optimal therapy for adults 60 years of age or younger with newly diagnosed ALL.
Burnett, Alan Kenneth   +41 more
core   +1 more source

Primary Cutaneous T-Cell Lymphoblastic Lymphoma: Case Report and Literature Review

open access: yesCase Reports in Hematology, 2019
Cutaneous involvement by precursor T-cell lymphoblastic leukemia/lymphoma (T-ALL/LBL) is rare, and almost all cases are seen in association with bone marrow, blood, and/or lymph node involvement.
Sharad Khurana   +4 more
doaj   +1 more source

A compendium of extracellular vesicle biogenesis inhibitors: From bench to bedside

open access: yesInterdisciplinary Medicine, EarlyView.
This review explores a decade of research on extracellular vesicles (EVs), detailing their biogenesis and roles in health and disease. It emphasizes EVs' relevance for potential medical applications covering various conditions such as cancer, neurodegeneration, inflammation, and infectious diseases, bridging experimental findings with clinical ...
Stefano Vecchione   +2 more
wiley   +1 more source

Selective targeting of NOTCH-1 for therapeutic purposes in xenograft models of T-acute lymphoblastic leukemia [PDF]

open access: yes, 2013
T-cell acute lymphoblastic leukemia (T-ALL) is an heterogeneous disease, characterized by several genetic alterations and polymorphic clinical features both in children and adults.
Agnusdei, Valentina
core  

Genetic analysis of primary lung interdigitating dendritic cell sarcomas

open access: yesThe Journal of Pathology, EarlyView.
Abstract Interdigitating dendritic cell sarcomas (IDCSs) are rare tumors that commonly arise in the hematopoietic system and rarely outside. The genetic drivers of IDCS carcinogenesis are unknown; therefore, therapeutic options are limited. We investigated somatic gene mutations and copy‐number alterations (CNAs) in nine IDCSs arising in the lung by ...
Mikhail S Ermakov   +6 more
wiley   +1 more source

Histiocytosis development and clinical variation through the lens of genomics

open access: yesThe Journal of Pathology, EarlyView.
Abstract Histiocytic neoplasms are rare haematologic diseases characterised by clonal expansions of cells with a monocyte, macrophage or dendritic cell phenotype. Their clinical manifestations are diverse, ranging from indolent lesions to aggressive systemic disease.
Paul G Kemps   +3 more
wiley   +1 more source

Additional file 1 of Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma

open access: yes, 2022
Additional file 1 : Supplementary Figure 1. Flow cytometry analysis on the anti-CD7 CAR T-cells. Supplementary Figure 2. Cytotoxicity analysis of the anti-CD7 CAR T-cells. Supplementary Figure 3. Timeline of treatments and responses. Supplementary Figure 4. T-cell fractions in the PB post CAR T-cells infusion. Supplementary Table 1.
Dai, Hai-ping   +9 more
openaire   +1 more source

Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity

open access: yesVIEW, EarlyView.
Cancer cells are vulnerable to oxidative stress, yet exploit immune tolerance to escape destruction. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS).
Manuela Calin   +3 more
wiley   +1 more source

Chromosome 21 in pediatric B-cell precursor acute lymphoblastic leukemia [PDF]

open access: yes, 2022
Chromosome 21 aberrations are often found in pediatric B-cell precursor acute lymphoblastic leukemia. In the thesis, the relation between chromosome 21 aberrations, frequent mutations, sensitivity to targeted therapies and leukemia is ...
Hormann, Femke
core   +2 more sources

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

open access: yesVIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Home - About - Disclaimer - Privacy